InterMune Lung Drug Is Backed by European Panel, Shares Double
Shares of drugmaker InterMune have more than doubled in premarket trading after a European advisory panel backed the company’s experimental lung treatment Esbriet (pirfenidone), something the biotech failed to accomplish in the…